Evolution of antibiotic resistance at low antibiotic concentrations including selection below the minimal selective concentration by Stanton, IC et al.
ARTICLE
Evolution of antibiotic resistance at low antibiotic
concentrations including selection below the
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Isobel C. Stanton 1, Aimee K. Murray 1, Lihong Zhang 1, Jason Snape2 & William H. Gaze 1✉
Determining the selective potential of antibiotics at environmental concentrations is critical
for designing effective strategies to limit selection for antibiotic resistance. This study
determined the minimal selective concentrations (MSCs) for macrolide and fluoroquinolone
antibiotics included on the European Commissionʼs Water Framework Directive’s priority
hazardous substances Watch List. The macrolides demonstrated positive selection for ermF
at concentrations 1–2 orders of magnitude greater (>500 and <750 µg/L) than measured
environmental concentrations (MECs). Ciprofloxacin illustrated positive selection for intI1 at
concentrations similar to current MECs (>7.8 and <15.6 µg/L). This highlights the need for
compound specific assessment of selective potential. In addition, a sub-MSC selective win-
dow defined by the minimal increased persistence concentration (MIPC) is described. Dif-
ferential rates of negative selection (or persistence) were associated with elevated
prevalence relative to the no antibiotic control below the MSC. This increased persistence
leads to opportunities for further selection over time and risk of human exposure and
environmental transmission.
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Antibiotic concentrations found in the environment,released from anthropogenic sources1,2, are lower (ng/L–µg/L)3 than minimum inhibitory concentrations (MICs).
Traditionally these concentrations have not been regarded as
posing a risk in terms of selecting for antimicrobial resistance
(AMR). However, in research published in 2011 and 2014, single
species competition assays determined that selection occurs at
concentrations considerably lower than MICs, with the lowest
selective concentration (where the resistant strain is enriched over
the susceptible) termed the “minimal selective concentration”
(MSC)4,5. MSCs were determined for various compounds, e.g.,
100 ng/L for ciprofloxacin to 3 mg/L for erythromycin, in
Escherichia coli strains carrying both chromosomal and plasmid
borne resistance mechanisms4,5.
Subsequently, attempts have been made to determine MSCs of
antibiotics in complex microbial communities more representa-
tive of human, animal and environmental microbiomes. One
study investigated the selective potential of tetracycline in a model
biofilm6 establishing that the prevalence of tetA and tetG tetra-
cycline resistance genes was significantly higher at 1 µg/L com-
pared to a no antibiotic control6. The same team also
demonstrated significant increase in resistance to ciprofloxacin in
E. coli isolated from a complex community in a test tube system
and in a biofilm system (at 5 and 10 µg/L of ciprofloxacin,
respectively) in comparison to a no antibiotic control7. A more
recent study undertook evolution experiments similar to those
used by Gullberg et al.5 in laboratory batch microcosms, but with
a complex microbial community rather than single species
inoculum. A MSC of cefotaxime was determined as 0.4 µg/L using
qPCR to track prevalence of the blaCTX-M genes over time8.
Data using both single species and complex community
experiments suggest that antibiotic concentrations found in
environmental settings may select for AMR9. Data has been
published showing associations between environmental AMR
exposure and negative health outcomes in humans. One study
determined a link between surfing, and therefore higher exposure
to bathing waters, and increased gut carriage of CTX-M-
producing E. coli in comparison to non-surfers10. It is critical
to determine MSCs for antibiotics and co-selective agents, as
there is currently no requirement and no agreed test guidelines to
test selective potential. Mitigation strategies may be required to
reduce selection for AMR in the environment reducing the
probability of environmental transmission11 and evolution of new
resistant strains.
In 2015, the European Commission produced a report with a
list of 10 priority substances or groups of substances which are
potentially detrimental to the aquatic environment and require
better monitoring. This list included the three macrolide anti-
biotics (azithromycin, clarithromycin and erythromycin). To
determine which compounds should be placed on the Watch List,
predicted no effect concentrations (PNECs) were compared to
predicted environmental concentrations (PECs) for all three
antibiotics, and measured environmental concentrations (MECs),
for azithromycin and clarithromycin. Toxicity data for Cer-
iodaphnia dubia, Anabaena flos-aquae and Synechococcus leo-
poldenisis were used to determine PNECs for azithromycin,
clarithromycin and erythromycin, respectively. In all cases the
PECs and MECs exceeded the PNECs generating unacceptable
risk quotients (RQs) > 112. In 2018, the Watch List was updated
with the continued inclusion of the macrolides and the addition
of antibiotics ciprofloxacin and amoxicillin13.
Macrolides inhibit protein synthesis in bacterial cells by
binding to the 23S rRNA component of the 50S subunit of the
ribosome. This prevents newly synthesised peptides passing
through the ribosome tunnel and, subsequently, translation14,15.
There are a range of mechanisms that bacteria employ to resist
macrolides including rRNA methylases, efflux pumps (both ATP-
binding transporters and major facilitators), esterases and phos-
phorylases16. Macrolides have been detected in a variety of
environmental settings. Concentrations range from ng/L to µg/L
with a maximum MEC (excluding unusually high concentrations
from pharmaceutical production effluents, for example) of 4 µg/L
of erythromycin-H2O, a metabolite of erythromycin which is
thought to select for resistance genes17,18, measured in surface
water in the Jianhan Plain, China19.
Fluoroquinolones (FQs) are a synthetic class of broad spec-
turm antibiotics which has led to them being used extensively
worldwide20,21. In 2012, ciprofloxacin was the most highly pre-
scribed FQ in European countries accounting for 71% of
consumption22,23. This class of antibiotics works by binding to,
and inhibiting, bacterial type II topoisomerases which are
important for cellular processes including DNA replication21.
Due to the extensive FQ use in the clinic, many mechanisms
conferring resistance to FQs have emerged20. These include
mutation of the target site and transferable resistance genes such
as qnr genes that encode proteins that block the target site21.
Ciprofloxacin has been measured as high as 31 mg/L in phar-
maceutical effluent in India24, although a median concentration
of 0.12 µg/L was calculated using the Umweltbundesamt (German
Environment Agency) “Pharmaceuticals in the environment”
database (excluding values where ciprofloxacin was below the
detection limit)25. This is more indicative of typical environ-
mental concentrations of ciprofloxacin.
The aim of this study was to investigate whether current MECs
of azithromycin, clarithromycin, erythromycin and ciprofloxacin
select for AMR and to determine the MSCs for each compound.
Evolution experiments, as previously described8, were performed
with a complex microbial community inoculum in a simple
reproducible experimental system with greater bacterial and
resistance gene diversity, and therefore realism, than single spe-
cies model systems. A MSC of tetracycline was also determined to
compare this method to the previously published model biofilm
system6. Providing policy makers and regulators with MSC data
is important as this can be used in combination with traditional
ecotoxicology data to determine safe discharge levels of anti-
biotics and other antibacterial compounds, protecting environ-
mental and human health respectively9,26,27.
Here we show that the three macrolide antibiotics select for
AMR at concentrations considerably higher than those found
typically in environmental settings but that ciprofloxacin selects
for AMR at concentrations more representative of those found in
the environment. We also demonstrate a selective window below
the MSC which we have termed the minimal increased persis-
tence concentration (MIPC).
Results
Assessing the selective potential of macrolides. Five macrolide
resistance targets (ermB, ermF, mef family, mphA and msrD) were
selected to quantify with qPCR as they are commonly reported
from a range of Gram positive and Gram negative bacteria16. In
addition, mphA was the most common resistance gene found in
E. coli from clinical samples by Phuc Nguyen et al.28. Further,
ermB and ermF were suggested as genetic indicator determinants
for assessing resistance to macrolides in the environment29.
Selection for the intI1 gene was also determined. IntI1 encodes
the class 1 integron integrase gene. Class 1 integrons have been
frequently described as good markers of anthropogenic pollution
and of AMR prevalence as they integrate a wide range of anti-
biotic and biocide resistance genes30–34.
A review of current macrolide concentrations found in typical
aquatic environments (excluding concentrations where unusually
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high concentrations are found, for example pharmaceutical
effluent) for the three compounds, and the metabolite
erythromycin-H2O, was undertaken (Table 1) and initial anti-
biotic concentrations were chosen based on these values.
Supplementary Table 1 showing the full list of concentrations
and the references can be found in the Supplementary
Information.
Initial range finding experiments investigated whether envir-
onmentally relevant concentrations (0.1, 1, 10 and 100 µg/L) of
macrolides select for the targeted resistance genes, Supplementary
Figs. 1–3. No significant positive selection for any of the genes, at
any concentration of macrolides, was observed. Investigation of
higher concentrations was then undertaken from 1000 to 10,000
µg/L for azithromycin and clarithromycin and at 1000, 10,000
and 100,000 µg/L for erythromycin (as it has been found to be less
potent than some of its semi-synthetic derivatives35) Supplemen-
tary Figs. 4–6.
For mphA, significant positive selection at extremely high
concentrations was observed (10,000 µg/L for azithromycin and
clarithromycin and 100,000 µg/L for erythromycin). Statistically
significant positive selection for ermF was observed to 90%
confidence at 1000 µg/L for azithromycin and erythromycin and
to 95% confidence for clarithromycin and at subsequent higher
concentrations for all three. No significant positive selection was
observed for ermB, msrD or the mef family, although some genes
showed increased persistence (i.e., rate of gene loss over the 7 day
period was reduced with increasing antibiotic concentration).
This suggested a concentration range between 100 and 1000
µg/L was required to determine more accurate lowest observable
effect concentrations (LOECs) and MSCs. A final range of
macrolide concentrations was chosen based on responses seen in
range finding experiments, these were 100, 250, 500, 750, 1000,
10,000 and 100,000 µg/L. While ermF, mphA and intI1 underwent
positive selection, only data for ermF is presented as a selective
effect for this gene was observed at the lowest concentration for
all three compounds. However, mphA and intI1 show a much
stronger response in terms of greater increases in gene prevalence
at higher antibiotic concentrations (Supplementary Figs. 7–12).
For all three macrolides, significant positive selection for ermF
was observed at 750 µg/L (Fig. 1a–c, respectively). Selection for
ermF was observed at 90% confidence at 750 µg/L by both
azithromycin (p= 0.0616, z=−1.541855, Dunn’s test, Δ= 5.03)
and erythromycin (p= 0.0663, z=−1.503557, Dunn’s test, Δ=
1.89) and by clarithromycin to 95% confidence (p= 0.0336, z=
−1.830510, Dunn’s test, Δ= 3.22) but no significant selection was
seen for all of the macrolides at 500 µg/L compared to the no
antibiotic control (Fig. 1). We, therefore, determined 750 µg/L as
the LOEC for all three macrolides.
For mphA, selection by azithromycin occurred at 1000 (p=
9.21e−5, t= 4.470, Gamma (log) GLM, Δ= 67.70), 10,000 (p=
0.000413, t= 3.941, Gamma (log) GLM, Δ= 43.27) and 100,000
µg/L (p= 0.003762, t= 3.125, Gamma (log) GLM, Δ= 21.30).
For clarithromycin, no significant increase of mphA prevalence,
in comparison to the no antibiotic control, was seen until 100,000
µg/L (p= 0.0446, z=−1.699673, Dunn’s test (difference), Δ=
8.66). Similarly, erythromycin did not positively select for mphA
until 100,000 µg/L (p= 0.0361, z=−1.797731, Dunn’s test, Δ=
26.56). Graphs for these data can be seen in Supplementary
Figs. 7, 9 and 11 for azithromycin, clarithromycin and
erythromycin, respectively.
In the presence of azithromycin, intI1 showed a significant
increase, compared to the no antibiotic control, to 90%
confidence at 1000 µg/L (p= 0.0886, t=−1.756, Gamma
(inverse) GLM, Δ= 415.64), 10,000 µg/L (p= 0.0894, t=
−1.752 Gamma (inverse) GLM, Δ= 288.75) and 100,000 µg/L
(p= 0.0932, t=−1.731, Gamma (inverse) GLM, Δ= 125.42). An
increase in intI1 prevalence in the presence of clarithromycin,
compared to the no antibiotic control, was observed only at
100,000 µg/L (p= 1.46e−05, t= 5.105, Gaussian GLM (differ-
ence), Δ= 1.81). Erythromycin also selected for intI1, in
comparison to the no antibiotic control, at 100,000 µg/L (p=
0.0142, z=−2.191057, Dunn’s test, Δ= 10.63). Graphs for this
data can be seen in Supplementary Figs. 8, 10 and 12 for
azithromycin, clarithromycin and erythromycin, respectively.
It was not possible to determine a MSC for selection of ermF by
azithromycin and clarithromycin as the trendline was always
above the x-axis for both. The MSC is defined where the line of
best fit crosses the x-axis (Supplementary Figs. 13 and 14,
respectively). A MSC of erythromycin, however, was calculated
(Fig. 2) and was 514.1 µg/L for ermF.
To determine if mutation based resistance to macrolides
occurred below the LOEC, phenotypic resistance was quantified
at a range of azithromycin concentrations. No significant
selection for resistance was observed for Enterobacteriaceae spp.
on Chromocult agar, Staphylococci spp. on Mannitol-salt agar or
bacteria able to grow on Mueller-Hinton agar at 100 µg/L.
Although some increase in resistance was observed at 1000 µg/L,
this was not significant (Supplementary Fig. 15).
Metagenome analysis was undertaken on a subset of samples
from macrolide selection experiments as this was the main focus
of the study and has not been investigated by previous studies.
Metagenome analysis of tetracycline and ciprofloxacin selection
has, however, been previously investigated in studies by
Lundström et al.6 and Kraupner et al.7. Three replicates were
taken from each treatment including the LOEC for all three
macrolides (750 µg/L), a concentration below this (250 µg/L) and
concentrations higher than this where a strong selective effect is
seen by intI1 (1000, 10,000 and 100,000 µg/L).
Metagenome analysis enabled the relative abundance of all
characterised macrolide–lincosamide–streptogramin (MLS) resis-
tance genes to be determined as a function of macrolide
concentration (Fig. 3). A significant difference in MLS gene
prevalence was observed for both azithromycin (p= 0.0280, z=
−1.911797, Dunn’s test, Δ= 8.84) and erythromycin (p= 0.0843,
z=−1.376494, Dunn’s test, Δ= 0.72) at 10,000 but not
for clarithromycin. A significant difference was seen at 100,000
µg/L and for azithromycin (p= 0.0047, z=−2.600044, Dunn’s
test, Δ= 15.72) clarithromycin (p= 0.0089, z=−2.370629,
Dunn’s test, Δ= 5.16) and erythromycin (p= 0.0109, z=
−2.294157, Dunn’s test, Δ= 5.40) compared to the no antibiotic
control.
We also observed some individual macrolide genes increasing
in prevalence, compared to the no antibiotic control, at 250 µg/L,
Supplementary Figs. 16–18. This is currently lower than our
LOEC and MSC defined by ermF. We, therefore, quantified
molecular prevalence of two of these genes (ermB and macB) with
qPCR, as it has been deemed to be a more sensitive approach than
metagenomics and considers gene prevalence in the entire
community rather than just the sequenced fraction6. These genes
were chosen to represent the resistance genes observed increasing
in relative abundance at lower concentrations. MacA was not
quantified as it is always found in conjunction with macB as they
Table 1 Environmental concentrations of macrolides.
Antibiotic Mean (µg/L) Maximum (µg/L)
Azithromycin 0.193 1.5
Clarithromycin 0.140 1
Erythromycin 0.225 2.42
Erythromycin-H2O 0.412 4
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encode 2 subunits of an ABC-type efflux pump—MacAB36,37.
Using qPCR, no positive selection was observed for these genes
(i.e., the prevalence of these genes did not increase over time in
comparison to the no antibiotic control), Supplementary Figs. 19
and 20.
Co-selection was observed at high concentrations of azithro-
mycin and clarithromycin, Supplementary Figs. 21–23. Resistance
to certain antibiotic classes appeared to be selected for at
relatively low concentrations of erythromycin (250 µg/L)
although if individual gene abundances were compared, a dose
dependent response of prevalence did not demonstrate an
association with antibiotic concentration until much higher
concentrations suggesting this may be an artefact (Supplementary
Fig. 24).
The metagenome analyses also provided information on
community structure. Replicates from all treatments were found
to be dominated by E. coli and unclassified Escherichia spp. but
also included a range of other Gram negative and Gram
positive taxa.
Replicates treated with azithromycin and clarithromycin
became less diverse with increasing concentration of antibiotic,
but there was a less clear pattern when samples were treated with
erythromycin. Many species were undetectable when samples
were treated with 100,000 µg/L of the specific macrolide,
indicating exposure to high concentrations reduced community
diversity (Supplementary Figs. 25–27).
Assessing the selective potential of ciprofloxacin. The Enter-
obacteriaceae clinical breakpoint from the EUCAST database was
chosen as the maximum concentration for ciprofloxacin—1000
µg/L (EUCAST, Clinical breakpoints—bacteria (v. 4)). Sub-
sequent concentrations were a twofold dilution series down to
0.98 µg/L.
qnrS was the class specific gene targeted by qPCR to investigate
selection by ciprofloxacin at a range of concentrations. It is the
most common gene identified from clinical Enterobacteriaceae
isolates, is mobile and is often found in environmental
strains21,38. In addition, qnr genes have been reported embedded
in complex class 1 integrons39. The intI1 gene was also
enumerated to investigate selection by ciprofloxacin. No sig-
nificant selection for qnrS was observed at any concentration
(Supplementary Fig. 28). For the intI1 dataset, the Dunnett’s/
Dunn’s approach did not align well to the biological effect. No
significant selection was observed with the Dunn’s test until 125
µg/L, however a clear biological effect can be seen at 15.625 µg/L.
For this reason, GLM was used. This determined a significant
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Fig. 1 Selection for ermF by macrolide antibiotics. a Azithromycin. b Clarithromycin. c Erythromycin. *Significant positive selection to 90% confidence in
comparison to the no antibiotic control. **Significant positive selection to 95% confidence in comparison to the no antibiotic control. n= 5 replicates per
concentration. One high outlier replicate has been removed from the clarithromycin experiment (day 7, 250 µg/L). Boxplots follow the Tukey’s
representation.
Fig. 2 Selection coefficient graph for ermF by erythromycin. Selection
coefficient values were determined as described previously5. These were
plotted with a line of best fit (polynomial regression line order 4, R2=
0.1709, y=−2.544e−12x4+ 1.564e−09x3+ 2.59e−06x2− 0.001432x+
0.01684). Here the line of best fit crosses the x-axis at 514.1 µg/L and this
is defined as the MSC for this gene selected for by this compound. n= 5
replicates per concentration.
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effect to 90% confidence at 15.625 (p= 0.0634, t= 1.901, GLM
Gamma (identity), Δ= 14.81) and 31.25 µg/L (p= 0.0553, t=
1.964, GLM Gamma (identity), Δ= 21.01) and to 95% confidence
at 62.5 (p= 0.0491, t= 2.019, GLM Gamma (identity), Δ=
32.39), 125 (p= 0.0470, t= 2.039, GLM Gamma (identity), Δ=
40.04), 250 (p= 0.0437, t= 2.071, GLM Gamma (identity),
Δ= 63.89), 500 (p= 0.0438, t= 2.070, GLM Gamma (identity),
Δ= 62.75) and 1000 µg/L (p= 0.0429, t= 2.080, GLM Gamma
(identity), Δ= 75.78) (Fig. 4).
By plotting the data as selection coefficients, a MSC of 10.77
µg/L was determined (Fig. 5).
Comparing in vitro assays for determining MSCs. To determine
whether MSCs/LOECs calculated here were comparable to the
biofilm microcosm assay developed by Lundström et al.6, tetG
was quantified using qPCR in a selection experiment run for
7 days under tetracycline hydrochloride selection. Tetracycline
concentrations were selected to span concentrations where the
MSC was reported by Lundström et al.6 (i.e., 0.1, 1, 10 and 100
µg/L). Significant selection to 90% confidence was observed at 1
µg/L (p= 0.0784, z=−1.416214 Dunn’s test, Δ= 2.01), 10 µg/L
(p= 0.0658, z=−1.507583, Dunn’s test, Δ= 13.84) and 100 µg/L
(p= 0.0784, z=−1.416214, Dunn’s test, Δ= 11.42) in compar-
ison to the no antibiotic control for tetG at day 7 (Fig. 6a).
However, when data was analysed by comparing prevalence at
day 0–7 for each concentration as previously in this study, loss of
the tetG genes at all tetracycline concentrations tested (0.1–100
µg/L) was observed (Fig. 6b). The average starting prevalence of
tetG in the current study was 0.0096 and the highest prevalence at
the end of the 7 days was 4.3E−06. In the selection coefficient
graph produced for this dataset, no positive selection was
observed so a MSC could not be determined (Supplementary
Fig. 29).
Discussion
The data generated in this study suggests that, in this experi-
mental system, environmental concentrations of the three mac-
rolides do not positively select for macrolide resistance genes.
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Fig. 3 MLS resistance gene prevalence as a function of macrolide concentration. a Azithromycin. b Clarithromycin. c Erythromycin. *Significant increase
to 90% confidence in comparison to the no antibiotic control. **Significant increase to 95% confidence in comparison to the no antibiotic control. n= 3
replicates per concentration. Boxplots follow the Tukey’s representation.
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Fig. 4 Selection for intI1 by Ciprofloxacin. Significant selection for intI1 by
ciprofloxacin is seen at concentrations of 15.625 µg/L (p= 0.0634, Gamma
GLM) and higher. *Significant positive selection to 90% confidence in
comparison to the no antibiotic control. **Significant positive selection to
95% confidence in comparison to the no antibiotic control. n= 5 replicates
per concentration. Boxplot follows the Tukey’s representation.
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For all of the macrolides, significant positive selection for ermF
was observed at 750 µg/L but not at 500 µg/L.
The LOECs determined here are significantly higher than the
maximum MECs determined by the literature review (Table 1)
(1.5, 1, 2.4 and 4 µg/L for azithromycin, clarithromycin, ery-
thromycin and erythromycin-H2O, respectively).
By applying a tenfold assessment factor (as recommended by
the European Medicines Agency40) to 500 µg/L (i.e., the highest
no observable effect concentration (NOEC)) for azithromycin,
clarithromycin and erythromycin, a PNEC of 50 µg/L was
obtained. For erythromycin, a tenfold assessment factor can be
applied to the MSC (514.1 µg/L) to calculate a PNEC of 51.41 µg/
L. However, as macrolide resistance mechanisms developed by
bacteria are common to all three macrolides, we assume that they
will have an additive selective effect when all three compounds
are released together (although this has not been tested and
should be considered in future studies). These PNECs may still,
therefore, be underestimates when taking into account combined
exposure effects.
In the case of selection for intI1 and mphA using qPCR and the
MLS genes from the metagenome analysis, azithromycin appears
to be more selective than both clarithromycin and erythromycin,
whereas the latter two appear to correlate with each other. One
possible explanation is that clarithromycin and erythromycin are
more chemically similar to each other, containing a 14 member
lactone ring, whereas azithromycin contains a 15 member lactone
ring41. In addition, it has been shown that azithromycin is a more
potent drug than erythromycin35. Furthermore, one study
demonstrated lower MICs for azithromycin in comparison to
erythromycin and found it had increased potency in a range of
different bacterial species42.
MSCs and PNECs generated in this study are significantly
higher than the estimated PNECs for the selection of resistance
(PNECRs) calculated by Bengtsson-Palme and Larsson43 (azi-
thromycin (0.25 µg/L), clarithromycin (0.25 µg/L) and ery-
thromycin (1 µg/L))43, the freshwater PNECs reported by the
European Commission12 (azithromycin (0.09 µg/L), clari-
thromycin (0.13 µg/L) and erythromycin (0.2 µg/L))12 and the
PNEC in surface water determined by Le Page et al. (azi-
thromycin (0.019 µg/L), clarithromycin (0.084 µg/L) and ery-
thromycin (0.2 µg/L))26; but lie in between the MSCs determined
for erythromycin for chromosomal and plasmid based resistance
(200 µg/L and 3000 µg/L, respectively) determined in single spe-
cies assays by Gullberg et al.4. This suggests that current ecolo-
gical PNECs may be protective of resistance selection for
macrolides, but this may not be the case for all classes of
antibiotics8,26. The reasons behind these variations in selective
effect concentrations are complex. Gullberg et al.4 demonstrated
that resistance mechanism (e.g., location of mutation) and genetic
context influenced MSCs in a single host species system. It is also
likely that host identity affects MSC and Klümper et al.44 recently
demonstrated that when a focal E. coli strain was embedded
within a complex microbial community the MSC increased by
13–43 times44. Therefore, higher observed MSCs in complex
microbial communities, compared to single species assays, are
likely to be driven by biological processes as well as by less sen-
sitive detection methodologies used (e.g., flow cytometry of
fluorescently labelled isogenic strains compared to qPCR and
metagenomic approaches) and greater variation between repli-
cates due to the complexity of the system.
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Fig. 6 Persistence of tetG as a function of tetracycline concentration. a Persistence of tetG at day 7. b tetG prevalence at both day 0 and day 7.
*Significant increase to 90% confidence in comparison to the no antibiotic control. n = 3 replicates per concentration. Boxplots follow the Tukeyʼs
representation.
Fig. 5 Selection coefficient graph for intI1 by ciprofloxacin. Selection
coefficient values were determined as previously in Gullberg et al.5. These
were plotted with a line of best fit (polynomial regression line, order 4,
R2= 0.4396, y= 0.1093+ 0.293x–0.5274x2+ 0.1921x3− 0.0188x4).
Here the line of best fit crosses the x-axis at 10.77 µg/L and this is
defined as the MSC. Plotted here is a square root transformation of the
ciprofloxacin concentrations 0.9765625, 1.953125, 3.90625, 7.8125, 15.625
and 31.25 µg/L. n= 5 replicates per concentration.
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The decrease in diversity of species observed in the metagen-
ome for all three macrolides, especially at 100,000 µg/L, could
explain why a significant decrease in prevalence was seen for
ermF at 100,000 µg/L. Presumably, the bacterial species pre-
dominantly harbouring this gene were significantly reduced in
number by this concentration of macrolide.
Whilst the experimental population is dominated by E. coli and
Escherichia spp, there is still a diverse population of bacterial
species present. This is not unexpected as the inoculum used was
raw wastewater and E. coli is a faecal coliform bacterium45. The
laboratory conditions that these experiments were undertaken in
also favour the growth conditions of E. coli and other Escherichia
spp. These species are Gram negative opportunistic pathogens
and are, therefore, of great concern in regards to the emergence of
resistance. In addition, E. coli has been shown to be a reservoir for
the macrolide resistance gene mphA28, which was consistently the
resistance gene found to be one of the most abundant genes in all
three metagenome datasets.
Of all the class specific genes tested, three targets (ermB, msrD
and the mef gene family) did not undergo positive selection at any
antibiotic concentration, even at clinically relevant concentra-
tions. One possible explanation might be the low prevalence of
these genes in the population in our initial inoculum, although
ermF consistently demonstrated the lowest starting prevalence of
all macrolide resistance genes quantified (except for msrD, which
was 0.002 lower) but still demonstrated enrichment with
increasing macrolide concentration. It is also possible that the
bacterial taxa carrying ermB, msrD and mef were outcompeted by
other resistant taxa with intrinsic or acquired resistance conferred
by other mechanisms.
For ciprofloxacin, we determined a MSC of 10.77 µg/L, and
with an assessment factor of 10 applied, a PNEC of 1.077 µg/L.
These values are in the same order of magnitude as ciprofloxacin
MECs reported in aquatic environments (not including phar-
maceutical manufacturing waste pollution)46. Ciprofloxacin levels
in hospital wastewater influent in Switzerland, for example, have
been reported between 3 and 87 µg/L47. This means that selection
for FQ resistance may occur in certain environmental settings
polluted with particularly high levels of ciprofloxacin. Further-
more, as this MSC is based on intI1 selection, it is likely genes
conferring resistance to different antimicrobials may also be co-
selected by ciprofloxacin at these low concentrations. This is due
to the fact that first; some class 1 integron backbones also contain
the sul1 gene (which confers resistance to sulphonamides) and
the partly functional, multi-drug efflux pump qacΔ1 (which
confers resistance to quaternary ammonium compounds); and
second; class 1 integron arrays are known to carry a variety of
different AMR gene cassettes48. A class specific qPCR gene target
(qnrS) was also enumerated, but no selection was observed.
Previously, metagenome analyses have been performed in the
same experimental system, where untreated wastewater was
exposed to ciprofloxacin at 500 µg/L. Even at this comparatively
high concentration, no significant increase in known FQ resis-
tance genes was observed. However, prevalence of genes con-
ferring resistance to several other antibiotic classes did increase
significantly49. This suggests that there may be uncharacterised
FQ resistance mechanisms that are selected for below the MSC
established by intI1 prevalence in this study.
The ciprofloxacin MSC determined here (10.77 µg/L) is similar
to the LOEC determined in the biofilm (10 µg/L) and test tube (5
µg/L) experiments by Kraupner et al.7 but are, as with the mac-
rolide compounds, higher than the PNECR calculated by
Bengtsson-Palme and Larsson43 (0.064 µg/L) and the freshwater
PNEC calculated by the European Commission12 (0.089 µg/L).
The value determined by the European Commission12 has,
however, had an assessment factor of 50 applied meaning the
NOEC was 4.45 µg/L, which is in the same order of magnitude as
the MSC determined in the current study. It is also in the same
order of magnitude as the MSCs determined for a variety of
chromosomal mutations, by Gullberg et al.5, that ranged from 0.1
to 2.5 µg/L and the PNEC in surface water determined for
ciprofloxacin (0.565 µg/L) by Le Page et al.26 for cyanobacteria.
This agreement in selective effect concentrations across several
studies by different research groups suggests that, for cipro-
floxacin at least, we can be fairly confident that positive selection
occurs in the range of current MECs. The system used here
maximises numbers of bacterial generations, and therefore
opportunities to observe selection, using high temperature and
nutrient conditions. It still, however, generated comparable data
to the lower temperature/nutrient flow through biofilm system
used previously6.
A comparison of the method used in this study and that used
previously by Lundström et al.6 was made by undertaking a tet-
racycline selection experiment. A significant increase in prevalence
of tetG was observed at 1 µg/L compared to the no antibiotic
control (Fig. 6a) when considering only day 7 prevalence (at the
end of the experiment), as reported in Lundström et al.6. However,
when taking into account the starting prevalence, a reduction in
tetG prevalence over time was observed at all concentrations of
tetracycline tested (Fig. 6b). Therefore what was described by
Lundström et al.6 may have been due to increased persistence (i.e.,
reduced rate of negative selection) and not positive selection or
enrichment as suggested. The term MSC should be reserved for
the lowest concentration of antibiotic “where the resistant mutant
is enriched over the susceptible strain”50. A concentration above
which a significant increase in persistence is observed could
instead be defined as the minimal increased persistence con-
centration (MIPC). The MIPC is important as concentrations of
antibiotic above this will decrease the rate at which resistant
bacteria disappear from the environment. This will result in an
increased human exposure risk and the probability of subsequent
evolution in comparison to environments where no antibiotics are
present. It is less of a concern, however, than if positive selection
was occurring where numbers of resistance genes and resistant
bacteria increase over time. This raises concerns regarding a sub-
MSC persistence window (Fig. 7) where numbers of resistant
bacteria are higher than if there was no antibiotic present, even
though concentrations are below the MSC. Therefore, it could be
argued that regulators should be using the MIPC rather than
MSC/LOEC as the endpoint when determining safe discharge
limits for antimicrobials. The vastly different MSCs/LOECs for the
different antibiotics determined here demonstrates the importance
of individually testing the selective potential of all antibiotics and
other co-selective compounds. It is important that gene targets
used to determine selection endpoints by qPCR are appropriate
and this can be ensured using metagenome analysis to identify
genes enriched at the lowest antibiotic concentrations8. However,
the existence of uncharacterised resistance genes cannot be ruled
out, which is why phenotypic characterisation is still useful.
Although determining the MSC is important for evaluating the
selective effects of existing and new antibiotics, it should be used
in combination with other bacterial and ecological endpoints.
This will enable a more informed assessment of the risk these
compounds pose to the environment and indirectly to human
health through selection for AMR, as the MSC may not always be
the most protective endpoint. In addition it should be noted that
the MSC determines the threshold at which positive selection
occurs and does not give any insights into the magnitude of the
selective effect. For example the macrolide MSC/LOECs were
determined by ermF but the increase in prevalence was small,
whereas the LOEC determined for intI1and mphA was higher but
was associated with a much greater increase in prevalence.
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We also show, for the first time to our knowledge, that sub-
MSC concentrations, above the MIPC may also be important to
consider as they are likely to be associated with increased human
exposure risk, increased probability of resistance gene transfer
and increased AMR evolution due to greater numbers of resistant
bacteria being present in environmental settings. However, with
increased persistence the number of resistant bacteria or resis-
tance genes will decrease over time at antibiotic concentrations
above the MIPC whereas enrichment through positive selection
(at antibiotic concentrations above the MSC) will lead to
increased AMR over time, so the two phenomena are funda-
mentally different in terms of outcome. If the MIPC was used as
the selective endpoint when determining safe release limits, this
could decrease the PNECs of some antibiotics considerably.
Based on selection for AMR alone, this data would suggest that
the macrolides could be removed from the European Commis-
sion’s Water Framework Directive’s priority hazardous sub-
stances Watch List, whereas ciprofloxacin should remain.
However, the decision as to whether the macrolides remain on
the Watch List, are deprioritised, or are included as priority
substances will need to be based on whether the Watch List
monitoring data indicates that they pose an EU-wide ecological
risk or not.
Methods
Complex community sample collection. A grab sample of raw wastewater influent
was obtained from a small wastewater treatment plant in Falmouth, UK serving a
population of circa 43,000 in October 2015. Samples were frozen at −80 °C in 40mL
aliquots consisting of 20mL wastewater and 20mL 40% glycerol (Fisher).
Selection experiment. Samples were washed by pelleting bacteria by centrifuga-
tion at 3500 rpm, removing the supernatant and resuspending in the same volume
of 0.85% saline solution. This was repeated to remove existing, potentially selective
compounds. Iso-sensitest broth (Oxoid) was inoculated with 10% v/v of the washed
wastewater sample with the appropriate concentration of antibiotic (azithromycin
(Sigma-aldrich), clarithromycin (Molekula), erythromycin (Acros Organics),
ciprofloxacin (Sigma-Aldrich) or tetracycline hydrochloride (Fisher)). These were
incubated at 37 °C for 24 h, after which 50 µL of the culture was passaged in fresh
Table 2 Primer sequences for qPCR.
Gene Forward (5′–3′) Reverse (5′–3′) Reference
ermB TTGGATATTCACCGAACACTAGGG ATAGACAATACTTGCTCATAAGTAACGG 62
ermF TCTGGGAGGTTCCATTGTCCT ACTTTCAGGACCTACCTCATAGA This study
mef family GGTGTRYTAGTGGATCGTCA GMHCCAGCTGCTGCKATAAT This study
mphA TGGTGCATGGCGATCTCTAC GACGCGCTCCGTGTTGTC This study
msrD CAAGCTGCARAATACGAACAATTT CCGCAGCCCTYTCCAAT This study
tetG GCTAACGAGCCTCACCAAT TGCGAATGGTCTGCGTAGTA 6
intI1 GCCTTGATGTTACCCGAGAG GATCGGTCGAATGCGTGT 63
16S rRNA CGGTGAATACGTTCYCGG GGWTACCTTGTTACGACT 64
qnrS CGACGTGCTAACTTGCGTGA GGCATTGTTGGAAACTTGCA 65
macB subtype 1 CTGCCGTCTCGCAAAACCT GCACTGGCAGCAACATCAAC This study
macB subtype 2 CCCACACTCGAAGCGCTTTA TGTTGTGGGCGTGGTGGAAG This study
macB subtype 3 GCGTCAGCCACCTGTACTTCA TGAACCAGCTGTACTACGTCG This study
macB subtype 4 GCAGCAACACCATCGACATCTA ACAACACCAGGGTTTCAATCG This study
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Fig. 7 Effect of antibiotic concentration on the growth rate of bacteria. Diagrammatic representation of change of growth rate of susceptible bacteria
(blue line) and resistant bacteria (red line) with increasing antibiotic concentration. Graph adapted from Gullberg et al.5 to include a sub-MSC persistence
window (blue area), the area between the MIPC and the MSC. In both the green and blue area, the susceptible bacteria outcompete resistant bacteria.
In the sub-MSC persistence window (blue area), however, as growth rate of susceptible begins to decrease there is an overall change in the ratio of
resistant to susceptible bacteria and subsequently a difference in total number of resistant bacteria compared to if no antibiotic was present. It is not until
the MSC and then in the sub-MIC selective window (yellow area) that resistant bacteria are enriched over susceptible bacteria and positive selection for
resistance occurs.
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broth (5 mL) with the appropriate antibiotic concentrations. These experiments
were carried out over a 7 day period with passage every 24 h. In total, 1 mL of
samples was taken at day 0 and 7, centrifuged at 14,800 rpm for 3 min and the
pellet was resuspended in 1 mL of 20% glycerol and frozen at −80 °C.
DNA extraction. DNA was extracted from samples using the MO Bio UltraClean®
Microbial DNA Isolation Kit (now QIAGEN DNeasy UltraClean Microbial Kit,
12224-250), as per the manufacturer’s instructions. DNA was stored at −20 °C
until use.
Real-time PCR. The class specific macrolide resistance gene targets chosen were
ermB, ermF, mphA, msrD and mef family (which targeted genes mefA, mefE, mefI
and mefO), for ciprofloxacin the target was qnrS and for tetracycline the class
specific gene was tetG. The intI1 integrase gene was also targeted for both the
macrolide and ciprofloxacin experiment. Finally, the 16S rRNA gene, which has
been used as a proxy for bacterial cell number6,8, was also enumerated to determine
molecular prevalence (target gene copy number/16S rRNA copy number).
Genes tested and their corresponding primers are shown in Table 2.
qPCR using DNA extracted from the macrolide and tetracycline experiments
was undertaken using Brilliant III Ultra-Fast Sybr® Green QPCR Master Mix
(Agilent Technologies) on the Applied Biosystems StepOne™ machine. Cycling
conditions used included an initial cycling stage of 95 °C for 20 s, followed by 50
cycles of 95 °C for 10 s and 60 °C for 30 s. Reactions consisted of 10 µL of master
mix, 2 µL of primer pair (10 µM for all primers except 16S which was 9 µM), 0.6 µL
of ROX dye, 5 µL of diluted template and were made up to 20 µL with sterile water.
DNA extracted from the ciprofloxacin evolution experiment was analysed using
the PrimerDesign PrecisionPLUS MasterMix with pre-added ROX (PrimerDesign).
In total, 20 µL reactions consisted of 5 µL of diluted template, 10 µL of mastermix,
2 µL of primer pair (4.5 µM), 0.2 µL of BSA (20 mg/mL) and filter sterilised water
up to 20 µL total volume. Cycling conditions used were 10 min at 95 °C, 40 cycles
of 95 °C for 15 s and 60 °C for 1 min.
The two mastermixes were compared and no significant difference was seen
between copy numbers determined for the sample template DNA.
Plating experiment. As azithromycin has been shown to be more potent than the
natural compound, erythromycin35 and has a lower MIC42, a phenotypic resis-
tance experiment was only conducted on azithromycin as it was expected to show
the lowest response of the three macrolides.
Day 7 cultures from samples grown with azithromycin concentrations of 0, 100,
1000 and 10,000 µg/L were plated onto three different types of agar to determine
phenotypic resistance. These were Chromocult Coliform Agar Enhanced Selectivity
(Merck), for growing Enterobacteriaceae spp., Mannitol-salt agar (composition
according to HiMedia Laboratories Technical Data protocol), for Staphylococcus
spp., and the non-selective (in terms of bacterial diversity) Mueller-Hinton agar
(Oxoid). Serial dilutions of 100 µL of culture were plated onto agar with and
without azithromycin. For Chromocult agar, 16 mg/L azithromycin was used (the
clinical breakpoint for Salmonella Typhi and Shigella spp. (EUCAST, Clinical
breakpoints—bacteria (v 7.1)), and for Mannitol-salt and Muller-Hinton agar 2
mg/L was used (the clinical breakpoint for Staphylococcus spp. (EUCAST, Clinical
breakpoints—bacteria (v. 7.1))).
Metagenome sequencing. A subset of samples from the week long selection
experiments were chosen for metagenomic analysis. Three replicates from 0, 250,
750, 1000, 10,000 and 100,000 µg/L for all 3 macrolides were sequenced.
DNA was purified as described in Murray et al.8 using RNase A (Qiagen) and
AMPure XP beads (Beckman Coulter). Samples were sent to Exeter Sequencing
Centre. Libraries were prepared using the Nextera XT DNA Library Prep Kit and
paired end sequencing was undertaken on a HiSeq 2500.
Sequences were first trimmed for adaptor removal using Skewer51 and quality
was checked using FastQC52 and MultiQC53. Paired end reads were combined
using FLASH version 254 and MetaPlAn255 was used to assign bacterial species.
Heatmaps for species diversity were generated using Hclust256. Antibiotic
Resistance Gene Online Analysis Pipeline (ARGs-OAP) version 257 was used, with
default settings, to quantify relative abundance and diversity of AMR genes.
Statistics and reproducibility. The macrolide range finding experiments and the
tetracycline experiments have three biological replicates per concentration. All
other experiments had five biological replicates per concentration.
All statistical analyses were performed in R Studio58. ANOVA and Dunnett’s
tests59 were performed for parametric data; and for non-parametric data, Kruskal
Wallis and Dunn’s tests60 were undertaken. Significance was determined to 90 and
95% confidence. As mixed community experiments are inherently noisy due to
founder effects and stochasticity, 90% confidence was also highlighted to show less
strong associations and will be more protective of selection for AMR in the
environment. Where the Dunnett’s/Dunn’s test did not align well to the biological
effect observed, a general linearised model (GLM) approach was used. Gaussian
and Gamma model families were explored with various link functions and the best
model fit was selected if assumptions were well met (if residuals were normal and
variances were homogenous) and by testing for overdispersion. Test statistics are
reported (z for Dunn’s test and t for GMLs) and Glass’s delta (Δ) is used to report
estimated effect size.
ANOVA/Kruskal Wallis tests were performed on the prevalence at day 0 to
ensure there was no variation between starting prevalences of samples. If a
difference was observed, the post-hoc tests described above were undertaken on the
difference between day 0 and 7. This is specified where appropriate.
Selection coefficient graphs were produced using the formula s= [ln
(prevalence at day 7/prevalence at day 0)]/7 as in Gullberg et al.5. Where genes
were determined by qPCR to have a copy number of zero at day 0, we determined a
pseudo value as these samples always showed presence of the gene at day 7. We
were able to conclude, therefore, that these genes were below the limit of detection
at the start of the experiment. The pseudo value was taken to be half of the
detection limit as an estimate. A line of best fit (testing linear and polynomial
models) was determined using the polynom package61 in R studio and a summary
of the models was produced. The model with the best fit was determined by
considering the R2 value and comparing models using a one-way ANOVA.
Definitions of selective endpoints. The lowest selective endpoint determined by
statistical analysis of qPCR data was defined as the LOEC and the highest con-
centration where no significant selection occurred as the no observable effect
concentration (NOEC). The selective endpoint determined by the selection coef-
ficient is defined as the MSC.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The datasets associated with Figs. 1–6 are included in this published article as a
Supplementary Data file. Metagenome sequence files have been deposited in the
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